Cost-effectiveness study of leflunomide versus methotrexate
Estudio coste-efectividad de leflunomida frente a metotrexato
Jordi Galván
Departamento Médico, Laboratorios GEBRO PHARMA S.A., Barcelona, Spain
Read
3986
Timeswas read the article
2118
Total PDF
1868
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 1 | 1 | 2 |
| 2025 5 | 57 | 30 | 87 |
| 2025 4 | 50 | 28 | 78 |
| 2025 3 | 58 | 29 | 87 |
| 2025 2 | 48 | 22 | 70 |
| 2025 1 | 48 | 41 | 89 |
| 2024 12 | 22 | 27 | 49 |
| 2024 11 | 49 | 60 | 109 |
| 2024 10 | 31 | 29 | 60 |
| 2024 9 | 22 | 14 | 36 |
| 2024 8 | 41 | 27 | 68 |
| 2024 7 | 24 | 27 | 51 |
| 2024 6 | 23 | 23 | 46 |
| 2024 5 | 36 | 27 | 63 |
| 2024 4 | 33 | 30 | 63 |
| 2024 3 | 26 | 30 | 56 |
| 2024 2 | 26 | 19 | 45 |
| 2024 1 | 15 | 18 | 33 |
| 2023 12 | 12 | 32 | 44 |
| 2023 11 | 26 | 15 | 41 |
| 2023 10 | 22 | 26 | 48 |
| 2023 9 | 22 | 33 | 55 |
| 2023 8 | 27 | 18 | 45 |
| 2023 7 | 23 | 14 | 37 |
| 2023 6 | 24 | 20 | 44 |
| 2023 5 | 14 | 17 | 31 |
| 2023 4 | 12 | 6 | 18 |
| 2023 3 | 29 | 41 | 70 |
| 2023 2 | 18 | 53 | 71 |
| 2023 1 | 15 | 40 | 55 |
| 2022 12 | 22 | 35 | 57 |
| 2022 11 | 19 | 32 | 51 |
| 2022 10 | 23 | 38 | 61 |
| 2022 9 | 19 | 40 | 59 |
| 2022 8 | 22 | 48 | 70 |
| 2022 7 | 22 | 47 | 69 |
| 2022 6 | 18 | 36 | 54 |
| 2022 5 | 20 | 54 | 74 |
| 2022 4 | 22 | 48 | 70 |
| 2022 3 | 20 | 29 | 49 |
| 2022 2 | 22 | 36 | 58 |
| 2022 1 | 14 | 44 | 58 |
| 2021 12 | 22 | 43 | 65 |
| 2021 11 | 36 | 51 | 87 |
| 2021 10 | 19 | 41 | 60 |
| 2021 9 | 20 | 45 | 65 |
| 2021 8 | 17 | 46 | 63 |
| 2021 7 | 23 | 38 | 61 |
| 2021 6 | 17 | 45 | 62 |
| 2021 5 | 16 | 32 | 48 |
| 2021 4 | 35 | 83 | 118 |
| 2021 3 | 30 | 35 | 65 |
| 2021 2 | 22 | 35 | 57 |
| 2021 1 | 23 | 18 | 41 |
| 2020 12 | 24 | 25 | 49 |
| 2020 11 | 12 | 22 | 34 |
| 2020 10 | 7 | 10 | 17 |
| 2020 9 | 21 | 29 | 50 |
| 2020 8 | 17 | 23 | 40 |
| 2020 7 | 10 | 7 | 17 |
| 2020 6 | 16 | 22 | 38 |
| 2020 5 | 14 | 23 | 37 |
| 2020 4 | 19 | 20 | 39 |
| 2020 3 | 12 | 18 | 30 |
| 2020 2 | 2 | 0 | 2 |
| 2020 1 | 4 | 0 | 4 |
| 2019 9 | 6 | 0 | 6 |
| 2019 6 | 2 | 0 | 2 |
| 2019 3 | 2 | 0 | 2 |
| 2019 1 | 2 | 0 | 2 |
| 2018 5 | 3 | 1 | 4 |
| 2018 4 | 20 | 9 | 29 |
| 2018 3 | 14 | 10 | 24 |
| 2018 2 | 19 | 2 | 21 |
| 2018 1 | 12 | 3 | 15 |
| 2017 12 | 7 | 3 | 10 |
| 2017 11 | 11 | 3 | 14 |
| 2017 10 | 7 | 4 | 11 |
| 2017 9 | 7 | 4 | 11 |
| 2017 8 | 8 | 10 | 18 |
| 2017 7 | 12 | 7 | 19 |
| 2017 6 | 13 | 7 | 20 |
| 2017 5 | 18 | 7 | 25 |
| 2017 4 | 10 | 3 | 13 |
| 2017 3 | 14 | 3 | 17 |
| 2017 2 | 6 | 5 | 11 |
| 2017 1 | 10 | 0 | 10 |
| 2016 12 | 27 | 10 | 37 |
| 2016 11 | 15 | 1 | 16 |
| 2016 10 | 30 | 10 | 40 |
| 2016 9 | 25 | 6 | 31 |
| 2016 8 | 20 | 7 | 27 |
| 2016 7 | 13 | 8 | 21 |
Show all
